Budget Impact of Selinexor in Multiple Myeloma

Share on: 

Multiple myeloma (MM) is a type of blood cancer that occurs in our body’s plasma cells. Rapidly reproducing, cancerous cells collect in bone marrow and crowd out healthy cells. Myeloma cells produce antibodies that, instead of fighting off infection, cause problems such as kidney and bone damage. 

MM is the second most predominant blood cancer. While significant advances in treatment have been made, the outlook remains poor for patients. 

Selinexor, a new treatment therapy for treatment-resistant MM, has been approved in the US in combination with dexamethasone. The approval is for patients with relapsed or refractory MM (RRMM) who have previously received three or more anti-myeloma treatment regimens. This was driven by positive clinical trial results, which demonstrated a 20% response rate. 

To understand the budget-impact of adopting this new treatment into a third-party payer plan, researchers from Karyopharm Therapeutics and RTI Health Solutions conducted a budget impact analysis. Using data collected from the SEER program, healthcare databases, and published literature, they calculated treatment costs. 

The model suggested that selinexor would create a small and manageable budget impact to payers, influenced in part by the low prevalence of penta-refractory MM.

See the abstract here.
Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J. US budget impact model for selinexor in relapsed or refractory multiple myeloma. Clinicoecon Outcomes Res. 2020 Jun 19;12:317-25. doi: 10.2147/CEOR.S251070

Staff Members: